Gamma knife surgery for 1-10 brain metastases without prophylactic whole-brain radiation therapy: analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria.
We evaluated the results of stereotactic radiosurgery (SRS) alone using gamma knife (GK) for selected patients with 1-10 brain metastases without prophylactic whole-brain radiation therapy (WBRT) among JLGK0901-eligible cases. Seven hundred seventy-eight consecutive cases meeting the following JLGK0901 study inclusion criteria were analyzed: (1) newly diagnosed brain metastases, (2) 1-10 brain lesions, (3) less than 10 cm(3) volume of the largest tumor, (4) less than 15 cm(3) total tumor volume, (5) no magnetic resonance (MR) findings of cerebrospinal fluid (CSF) dissemination, and (6) no impaired activity of daily living [<70 Karnofsky Performance Score (KPS)] due to extracranial disease. At initial treatment, all lesions were irradiated with SRS without upfront WBRT. Thereafter, enhanced magnetic resonance imaging (MRI) was applied every 2-3 months, and new distant lesions were appropriately retreated with SRS or WBRT. We divided patients according to tumor number: single lesion for group A (280 cases), 2 for group B (135), 3-4 for group C (148), 5-6 for group D (93), and 7-10 for group E (122). Differences among groups were compared in terms of overall, neurological, qualitative, and new-lesion-free survival (NLFS). Median age was 65 years (range 26-92 years). There were 505 men and 273 women. The primary organ was lung in 579 patients, gastrointestinal tract in 79, breast in 48, urinary tract in 34, and others/unknown in 38. Mean survival time was 0.72 years (0.83 years for 1, 0.69 years for 2, 0.69 years for 3-4, 0.59 years for 5-6, and 0.62 years for 7-10 metastases). On multivariate analysis, significant poor prognostic factors for overall survival (OS) were active systemic disease, poor (<70) initial KPS, and male gender. Neurological survival and qualitative survival at 1 year were 92.7% and 88.2%, respectively. NLFS at 6 months and 1 year were 69.8% and 43.8%, respectively. There were statistically significant differences in new lesion emergence between groups A and B and between groups B and C. SRS using GK provides excellent results in selected patients with 1-10 brain lesions, without prophylactic WBRT. This study revealed that brain lesion number has no effect on any of the four types of survivals, which is anticipated to be confirmed by the JLGK0901 study.
Serizawa
Toru
T
Tokyo Gamma Unit Center, Tsukiji Neurological Clinic, Tokyo, Japan. gamma-knife.serizawa@nifty.com
Hirai
Tatsuo
T
Nagano
Osamu
O
Higuchi
Yoshinori
Y
Matsuda
Shinji
S
Ono
Junichi
J
Saeki
Naokatsu
N
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016634:Radiosurgery / Q000379:methods*; D012189:Retrospective Studies; D016896:Treatment Outcome
N Engl J Med. 1990 Feb 22;322(8):494-500
2405271
JAMA. 2006 Jun 7;295(21):2483-91
16757720
Biometrics. 1982 Mar;38(1):163-70
7082758
J Neurosurg. 2008 Dec;109 Suppl:118-21
19123897
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
9128946
Acta Neurochir (Wien). 2005 Jul;147(7):721-6; discussion 726
15891808
J Neurosurg. 2006 Dec;105 Suppl:86-90
18503337
Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:41-9
9782234
J Neurosurg. 2000 Dec;93 Suppl 3:32-6
11143259
J Neurosurg. 2002 Dec;97(5 Suppl):484-8
12507082
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1279-83
12128130